Palettes of vaccines and immunostimulatory monoclonal antibodies for combination.
Various monoclonal antibodies (mAb) target immune system molecules to enhance immunity by costimulating T cells (i.e., CD137, OX40, CD40, GITR) or interfering in coinhibitory signals (i.e., CTLA-4, PD-1). These powerful agents can be guided by cancer vaccines to enhance immunity against tumor but not self tissues. Clinically powerful therapeutic synergies are at hand.
Melero
Ignacio
I
Gene Therapy Unit, Centro de Investigación Médica Aplicada (CIMA), Clinica Universitaria, Universidad de Navarra, Pamplona, Spain. imelero@unav.es
Martinez-Forero
Ivan
I
Dubrot
Juan
J
Suarez
Natalia
N
Palazón
Asis
A
Chen
Lieping
L
D000818:Animals; D000911:Antibodies, Monoclonal / Q000276:immunology / Q000627:therapeutic use*; D019496:Cancer Vaccines / Q000276:immunology / Q000627:therapeutic use*; D004338:Drug Combinations; D006801:Humans; D007109:Immunity; D008213:Lymphocyte Activation / Q000276:immunology; D009363:Neoplasm Proteins / Q000276:immunology; D009369:Neoplasms / Q000276:immunology / Q000628:therapy*; D013601:T-Lymphocytes / Q000276:immunology
D000911:Antibodies, Monoclonal; D019496:Cancer Vaccines; D004338:Drug Combinations; D009363:Neoplasm Proteins